- Home
- ELDN vs PBYI Comparison
ELDN vs PBYI Comparison
Compare ELDN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- PBYI
- Stock Information
- Founded
- ELDN 2004
- PBYI 2010
- Country
- ELDN United States
- PBYI United States
- Employees
- ELDN N/A
- PBYI N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ELDN Health Care
- PBYI Health Care
- Exchange
- ELDN Nasdaq
- PBYI Nasdaq
- Market Cap
- ELDN 202.4M
- PBYI 171.7M
- IPO Year
- ELDN N/A
- PBYI N/A
- Fundamental
- Price
- ELDN $2.37
- PBYI $4.52
- Analyst Decision
- ELDN Strong Buy
- PBYI Strong Buy
- Analyst Count
- ELDN 2
- PBYI 1
- Target Price
- ELDN $12.50
- PBYI $7.00
- AVG Volume (30 Days)
- ELDN 640.2K
- PBYI 592.1K
- Earning Date
- ELDN 11-11-2025
- PBYI 11-06-2025
- Dividend Yield
- ELDN N/A
- PBYI N/A
- EPS Growth
- ELDN N/A
- PBYI 434.29
- EPS
- ELDN 0.21
- PBYI 0.97
- Revenue
- ELDN N/A
- PBYI $238,062,000.00
- Revenue This Year
- ELDN N/A
- PBYI N/A
- Revenue Next Year
- ELDN N/A
- PBYI N/A
- P/E Ratio
- ELDN $11.10
- PBYI $4.65
- Revenue Growth
- ELDN N/A
- PBYI 8.63
- 52 Week Low
- ELDN $2.32
- PBYI $2.32
- 52 Week High
- ELDN $5.54
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- ELDN 35.17
- PBYI 51.02
- Support Level
- ELDN $2.41
- PBYI N/A
- Resistance Level
- ELDN $2.84
- PBYI $5.22
- Average True Range (ATR)
- ELDN 0.13
- PBYI 0.24
- MACD
- ELDN 0.00
- PBYI -0.28
- Stochastic Oscillator
- ELDN 10.48
- PBYI 83.09
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.